



Mobidiag Announces Release of Amplidiag® Stool Parasites (CE-IVD), a Multiplex PCR Test to Detect Parasites Directly from Stool Samples

ESPOO, Finland, August 29th, 2016 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the launch of its CE-IVD marked Amplidiag® Stool Parasites kit, a molecular test allowing detection of the main diarrhea causing stool parasites: *Giardia lamblia*, *Cryptosporidium spp.*, *Entamoeba histolytica* and *Dientamoeba fragilis*.

Pathogenic protozoa are the main causative agents of parasite-associated gastroenteritis due to their ability to multiply in humans. If not detected and treated in time, they can cause diarrhea and a wide variety of other prolonged symptoms, such as colitis, abdominal discomfort, and nausea, symptoms that compromise quality of human life. As a result, infections caused by stool parasites raise important public health challenges with a strong economic impact globally.

Amplidiag® Stool Parasites is a qualitative multiplex PCR test allowing cost-effective and fast analysis of the most common gastrointestinal parasites found in stool by reducing substantially the burden of microscopy, time to process samples and hands-on-time.

“Amplidiag® Stool Parasites comes in action when infection with stool parasites is suspected. This test allows to take faster and more reliable decisions for the patient. By winning the CE-IVD marking, Amplidiag® Stool Parasites adds up to the Amplidiag® product line, further expanding Mobidiag’s gastrointestinal test panels and making it one of the most comprehensive offer on the market” said Jan Wikstén, Sales Manager at Mobidiag.

This test is intended for use by trained and qualified clinical laboratory personnel only. Please read carefully the instructions found in the user manual and/or the labeling.

For more information, visit <http://mobidiag.com/products/amplidiag/stool-parasites/>

About Mobidiag

Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.

Mobidiag is able to address both high volume and on demand testing with:

- The Amplidiag® product line, innovative multiplex tests for gastrointestinal infections. Based on well-established real-time PCR technology, they ensure optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings.
- The Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results.
- The Novodiag® platform and associated panels (upcoming) is a fully automated solution and suitable for smaller volumes and labs.

Visit www.mobidiag.com for more information.

Contact

Mobidiag Ltd.

+358 10 5050 770

info@mobidiag.com